Broker snap: Panmure raises bid hopes at Tissue Regenix
12th Dec 2013 10:54
Panmure Gordon has hiked its target price for AIM-listed medical devices company Tissue Regenix (TRX) by over a fifth after the signing of new sales distribution agreements in the US, highlighting the possibility that the firm could become a bid target in the future. The firm said on Thursday that
Read moreTissue Regenix perks up on US distribution deal
12th Dec 2013 08:44
AIM-listed Tissue Regenix has agreed seven sales distribution agreements in the US to promote its DermaPure human skin replacement device into hospitals. Shares in the company jumped over 16% to 20.13p as the company confirmed it was on course for 2014 commercial launch for its first product to be
Read moreThursday broker round-up UPDATE
12th Dec 2013 08:13
British American Tabacco: Credit Suisse reduces target price from 3700p to 3550p and retains its outperform rating. City of London Inc Group: N+1 Singer cuts target price from 260p to 220p downgrading to hold. Diageo: Credit Suisse reduces target price from 2350p to 2200p and maintains an outperfo
Read moreTissue Regenix H1 losses creep up as it ramps-up for US launch
8th Oct 2013 09:17
First half losses increased slightly at regenerative medicine specialist Tissue Regenix as it drove its products further towards commercialisation with several senior appointments made in the US. The pre-revenue company generated losses of £2.3m for the six months to July 31st that were in line wi
Read more